Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition that develops and markets a treatment for patients with PNH, an ultra-rare and life-threatening disorder caused by chronic uncontrolled complement activation.